CD30 Ligand: Cloning, Characterisation and Biological Activities
Hodgkin’s disease (HD) is characterised by the presence of a small number (< 1% of total tumour mass) of the typical, presumed malignant Hodgkin and Reed-Sternberg (H-RS) cells in a hyperplastic background of normal, reactive lymphocytes, plasma cells, histiocytes, neutrophils, eosinophils, and stromal cells. The histopathological presentation and characteristic clinical features of HD correlate with an unbalanced production of multiple cytokines. H-RS cells produce various growth factors, cytokine receptors and activation antigens, implying a role for growth factors in the pathophysiology of HD. HD may therefore be characterised as a tumour of cytokine producing cells. The CD30 antigen has been described as a marker for cultured and primary H-RS cells, and found to be overexpressed in HD and some large cell anaplastic non-Hodgkin’s lymphoma cases. The molecular cloning of the CD30 antigen revealed that CD30 is a member of the tumour necrosis factor/nerve growth factor receptor superfamily. The cloning of the cognate for CD30, currently termed CD30 ligand, confirmed that the CD30 antigen functions as a cytokine receptor. Recombinant CD30 ligand is a type-II membrane-associated protein with pleiotropic biological activities for different CD30+ lymphoma types, but also normal immune system cells, predominantly T-cells. CD30L belongs to the emerging tumour necrosis factor ligand superfamily by virtue of homology to CD27L, CD40L, TNF and other members. These findings suggest that CD30-CD30L interactions could have a pathophysiological role in HD and large cell anaplastic lymphomas, and could also be involved in the activation and function of the immune system, particularly T-cell responses.
KeywordsLarge Cell Anaplastic Lymphoma CD30 Monoclonal Antibody CD30L Expression Cytokine Produce Cell Burkitt Lymphoma Cell Line
Unable to display preview. Download preview PDF.
- Gruss H-J, Herrmann F, Drexler HG (1994a) Hodgkin’s disease, a tumor of cytokine producing cells. Crit Rev Oncogen 5:473Google Scholar
- Herbst H, Stein H, Niedobitek G (1993) Epstein-Barr virus and CD30+ malignant lymphomas. Crit Rev Oncogen 4:91Google Scholar
- Kaplan HS (1980) Hodgkin’s disease. (Boston: Harvard University Press)Google Scholar
- Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, Perona G, Chilosi M, Menestrina F, Fiacchini M, Stein H, Pizzolo G (1994) Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin’s disease and correlate with clinical features and prognosis. J Clin Oncol 12:793PubMedGoogle Scholar
- Schwarting R, Gerdes J, Dürkop H, Falini B, Pileri S, Stein H (1989) BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 74:65Google Scholar
- Smith CA, Gruss H-J, Davis T, Anderson D, Farrah T, Baker E, Sutherland GR, Brannan CI, Copeland NG, Jenkins NA, Grabstein KH, Gliniak B, McAlister IB, Fanslow W, Alderson M, Falk B, Gimpel S, Gillis S, Din WS, Goodwin RG, Armitage RJ (1993) CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349PubMedCrossRefGoogle Scholar
- Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K (1985) The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848PubMedGoogle Scholar